Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Diasorin
Thumbnail
May 23, 2022

Diagnostics beat implants in the race to market

Roche had the most innovative approvals over the last five years – but took second place in terms of speed.

Thumbnail
October 14, 2021

Memed seeks partners for bacterial vs viral testing and more

The group’s ambitions are startling, but it will need cash and collaborators to realise them.

Article image
Vantage logo
August 09, 2021

Medtronic finally bags Intersect ENT

Article image
Vantage logo
April 12, 2021

Diasorin heads to the US with $1.8bn Luminex deal

And consolidation in the diagnostics space is only just beginning.

Article image
Vantage logo
January 20, 2021

Focus on Covid-19 does not distract the FDA

Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.

Article image
Vantage logo
July 13, 2020

Healthineers’ Covid-19 antibody test wins out in the UK

Article image
Vantage logo
June 18, 2020

The FDA gets aggressive with Covid-19 antibody tests

Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.

Article image
Vantage logo
May 04, 2020

Roche takes on Abbott in Covid-19 antibody testing

Robust specificity data mark Roche’s serological test out as a major competitor.

Article image
Vantage logo
April 27, 2020

The FDA waves through more antibody tests

Article image
Vantage logo
April 22, 2020

Covid-19 antibody tests face a very specific problem

With the prevalence of coronavirus infection running at about 5%, test manufacturers and regulators alike will have to guard against false positives.

Article image
Vantage logo
March 20, 2020

Genmark adds $100m in value on Covid-19 test authorisation

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

April 20, 2022

Genetic Medicine: The Next Generation

March 18, 2022

PD(L)anner - March 2022

View more...

Editor's Picks

Vantage logo
May 05, 2022

Bristol needs to get fresh

Vantage logo
May 04, 2022

The next generation of diabetes technology

Vantage logo
April 25, 2022

Nkarta: at least as good as Fate, at a tenth of the price

Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Vantage logo
May 01, 2020

US FDA approval tracker: April

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.